Coagulation factor ix recombinant Intravenous and Pancuronium Bromide

• Generic Name: coagulation factor ix
• Dosage Forms: n.a.
• Other Brand Names: Alphanine SD, Alprolix, BeneFIX, Idelvion, Ixinity, Mononine, Rebinyn, Rixubis, BeneFIX 250 Int'l Units, BeneFIX

Coagulation factor IX, recombinant injection is used to control bleeding episodes and prevent bleeding during surgery in patients with hemophilia B (congenital Factor IX deficiency).

Factor IX is a protein that is produced naturally in the body. Coagulation factor ix recombinant is a man-made protein produced to replicate the naturally occurring factor IX in the body. It is used to stop bleeding by helping the blood to clot in patients with hemophilia B.

Coagulation factor ix recombinant is to be given only by or under the supervision of your doctor or other health care professional.

• Generic Name: pancuronium
• Dosage Forms: n.a.
• Other Brand Names:

Production of skeletal muscle relaxation during surgery after general anesthesia has been induced.

Facilitation of endotracheal intubation; however, a neuromuscular blocking agent with a rapid onset of action (e.g., succinylcholine, rocuronium) generally preferred in emergency situations when rapid intubation is required.

Also used to facilitate mechanical ventilation in the ICU; however, manufacturer states insufficient data available to support dosage recommendations for such use. Whenever neuromuscular blocking agents are used in the ICU, consider benefits versus risks of such therapy and assess patients frequently to determine need for continued paralysis. (See Intensive Care Setting under Cautions.)

Compared with other neuromuscular blocking agents, pancuronium has a slow onset and long duration of action; therefore, not appropriate for emergency intubation but may be used for other indications (e.g., mechanical ventilation in the ICU) in which rapid onset and short duration of action are not as important.

Because of prominent vagolytic effects, generally should not be used in patients with preexisting tachycardia or in patients who cannot tolerate an increase in heart rate (e.g., those with cardiovascular disease).